HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients.

AbstractBACKGROUND:
Tumor recurrence, the chief reason for poor prognosis of glioma, is largely attributed to glioma stem cells (GSCs) and epithelial-mesenchymal transition (EMT). However, the mechanisms among them remain unknown. Here, we determined whether leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), known as a stem cell marker for colon cancer and gastric cancer, can serve as a novel GSC marker involved in EMT and a therapeutic target in glioma.
METHODS:
Stemness properties were examined in FACS-isolated LGR5+/LGR5- cells. Reported stem cell markers, EMT and the Wnt/β-catenin pathway were examined in stable LGR5 knockdown or overexpressed GSCs by Western Blot. The treatment experiment was performed in an intracranial orthotopic xenograft model by knockdown of LGR5 or by using the Wnt/β-catenin pathway inhibitor Wnt-C59. LGR5 expression was determined in 268 glioma specimens by immunohistochemistry.
RESULTS:
LGR5+ cells possessed stronger stemness properties compared to LGR5- cells. The expression of SOX2, Nanog, CD133, CD44, CD24 and EpCAM was modulated by LGR5. Both LGR5 knockdown and Wnt-C59 reduced tumor invasion and migration and blocked EMT by inhibiting the Wnt/β-catenin pathway in vitro and suppressed the intracranial orthotopic xenograft growth and prolonged the survival of xenograft mice in vivo. Moreover, LGR5 was positively correlated with Ki67, N-cadherin and WHO grade and negatively correlated with IDH1. Glioma patients with high expression of LGR5 showed significantly poorer prognosis.
CONCLUSIONS:
LGR5 is a new functional GSC marker and prognostic indicator that can promote EMT by activating the Wnt/β-catenin pathway and would thus be a novel therapeutic target for glioma.
AuthorsJin Zhang, Hongqing Cai, Lixin Sun, Panpan Zhan, Meng Chen, Feng Zhang, Yuliang Ran, Jinghai Wan
JournalJournal of experimental & clinical cancer research : CR (J Exp Clin Cancer Res) Vol. 37 Issue 1 Pg. 225 (Sep 12 2018) ISSN: 1756-9966 [Electronic] England
PMID30208924 (Publication Type: Journal Article)
Chemical References
  • Biomarkers, Tumor
  • CTNNB1 protein, human
  • LGR5 protein, human
  • Receptors, G-Protein-Coupled
  • beta Catenin
Topics
  • Adult
  • Aged
  • Animals
  • Biomarkers, Tumor (genetics)
  • Cell Line, Tumor
  • Disease-Free Survival
  • Epithelial-Mesenchymal Transition (genetics)
  • Female
  • Glioma (genetics, pathology)
  • Humans
  • Male
  • Mice
  • Middle Aged
  • Neoplastic Stem Cells (pathology)
  • Prognosis
  • Receptors, G-Protein-Coupled (genetics)
  • Wnt Signaling Pathway (genetics)
  • Xenograft Model Antitumor Assays
  • beta Catenin (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: